All In Biotech

Drug Trial Radar · NCT05154604

A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours

A Phase 1 Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1921 in Subjects With Advanced Malignant Solid Tumour .

Last checked: Nov 19, 2026Latest source record: Dec 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

156

Planned (sponsor's estimate)

Start

Dec 31, 2021

Primary completion

Aug 31, 2024

Study completion Aug 31, 2024

Sponsor

Sponsor type
Industry
First posted
Dec 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the safety and tolerability of SHR-A1921 in patients with advanced solid tumours, to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and/or recommended phase II dose (RP2D) of SHR-A1921

Conditions

  • Advanced Solid Tumours

Interventions

  • SHR-A1921Drug

    Treatment group: Subjects will receive an intravenous infusion of SHR-A1921 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limited Toxicity (DLT)Time frame: 21 Days (first cycle)
  2. Maximum Tolerable Dose (MTD)Time frame: 21 Days (first cycle)
  3. Recommended phase II dose (RP2D)Time frame: Screening up to dose escalation and expansion study completion, appropriately to 1 year
  4. Adverse EventsTime frame: Screening up to study completion, an average of 1 year

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.